Heather Wallace, Editor-in-Chief
University of Aberdeen, UK
ORCID: 0000-0003-2804-3304
PhD, FRCPath, FBTS, FRSC, FRSB FBPhS
European Registered Toxicologist
Heather is the Professor of Biochemical Pharmacology and Toxicology at the University of Aberdeen. Her research interests are in cancer therapeutics and prevention, selective drug delivery and the use of biomarkers for diagnosis and monitoring efficacy of anticancer drug therapy. She co-ordinates postgraduate teaching in Clinical Pharmacology, Drug Discovery and Development and Bio-Business.
Heather is President of the British Toxicology Society. She is a Fellow of the Royal College of Pathologists and is CPD Advisor for Toxicology at the College. She is also a Fellow of the following learned Societies: British Toxicology Society, Royal Society of Chemistry, Royal Society of Biology and British Pharmacological Society. Heather is a member of the UK Register of Toxicologists and a European Registered Toxicologist (since 2006). She is a Deputy Chair and a member of the Editorial Board of the Biochemical Journal and reviews for many journals and grant awarding agencies. She is a member of the EUROTOX Executive Committee.
Christie Sayes, Associate editor
Baylor University, US
ORCID: 0000-0002-5529-4101
Dr. Christie M. Sayes is an Associate Professor of Environmental Science and Toxicology at Baylor University. She is a subject matter expert in nanomaterial-related toxicology and exposure. Her activities include working with partners, collaborators, and clients in designing & directing studies and training & advising facility staff. She possesses a working knowledge of laboratory science and U.S. regulatory climates. Routine activities include data collection, analyses, and interpretation as well as results documentation and reporting. Christie received her PhD in Chemistry in 2005 from Rice University. Her dissertation focused on the nano-bio interface. In 2005, she joined The DuPont Company as Visiting Scientist and aided in the drafting of the DuPont-Environmental Defense Nano Risk Framework.
Ping-Kun Zhou, Associate editor
Beijing Institute of Radiation Medicine, China
ORCID: 0000-0001-7666-1209
Dr. Zhou is the director of the Department of Radiation Toxicology and Risk Assessment, Beijing Institute of Radiation Medicine. He has been working in the field of radiotoxicology and radiobiology, genotoxicology since 1985. His research topics include the low dose radiation effect and carcinogenesis, DNA damage and repair, and space radiobiology. He has ever worked as a visiting fellow in Paterson Institute for Cancer Research in Manchester, UK (1994-1995), and as a research fellow in Institute Curie in Paris, France (1998-2000). He has ever been as the chief scientist in charge of a “973” Program funded by the Ministry of Science and Technology of China. He was awarded the National Outstanding Youth Scientist Fund of NSFC, and the Outstanding Contributions Award to Radiation Research by the Asian Association for Radiation Research in 2013. He is now the President of the Chinese Society of Toxicology.
Rui Chen
Southeast University, China
Dr. Chen is the professor of environmental toxicology at School of Public Health, Southeast University, China. He completed his postdoctoral fellowship in Nelson institute of Environmental Medicine and UT Southwestern Medical Center. After his training, he joined the internal medicine faculty in the UT Southwestern Medical Center in Dallas, where he led a group researching mechanisms of cancer metabolism and epigenetic. Now his research mainly focuses on the study of environmental carcinogen related cancers and molecular mechanisms. Other research interests include the air pollution induced pulmonary toxicity, epigenetic and nanotoxicology. His research work have been published on top academic journals, including “Science”, “Nature Medicine” and “PNAS ”.
Dr. Chen was awarded Thousand Talent Program for Young Outstanding Scientists in 2015. He is now a fellow of the Chinese Society of Toxicology, Chinese Association of Environmental Mutagen Society.
Martin Philbert
University of Michigan, USA
Dr. Philbert is professor of toxicology and dean of the University of Michigan School of Public Health. His research focuses on the development of flexible polymer nanoplatforms for optical sensing of ions and small molecules and the early detection and treatment of brain tumors. Other research interests include the mitochondrial mechanisms of chemically-induced neuropathic states. He is the author of more than 200 peer-reviewed scholarly manuscripts, abstracts and book chapters.
Dr. Philbert chaired the US-EPA Chemical Assessment Advisory Committee that provides peer review of risk assessments produced under the auspices of the EPA’s Integrated Risk Information System and is a standing member of the Agency’s Science Advisory Board. He also served a four-year term on the National Advisory Environmental Health Sciences Council of the National Institute of Environmental Health Sciences and provides consultation to the federal agencies on a variety of issues surrounding emerging nanotechnologies, nanomedicine, health and safety.
Chris J. Powell
GlaxoSmithKline, UK
ORCID: 0000-0002-0441-2227
Dr Powell is Vice President of Translational Medicine and Comparative Pathobiology at GlaxoSmithKline Pharmaceuticals, with responsibility for experimental studies on the safety and efficacy of new medicines. Previously, he worked in the UK biopharmaceutical industry and was Reader in Pharmaceutical and Chemical Safety at St Bartholomew’s Hospital Medical College, University of London, where he led a group researching mechanisms of hepatotoxicity and non-genotoxic carcinogenicity. Chris trained in biochemistry, pharmacology and histopathology at the University of Wales, Imperial College London, the University of Surrey and he is a Fellow of the Royal College of Pathologists and the British Toxicology Society.
Dr Powell’s research interests include: mechanisms of toxicity and their application to human risk evaluation, non-genotoxic mechanisms of chemical carcinogenicity and the human translational relevance of experimental safety studies. He is a member of the Royal Society of Biology, the Society of Toxicology, the UK Pathology Society and is a regular speaker at scientific meetings.
Dr Powell has served on several Scientific Advisory Committees for the UK/EU Government and for the World Health Organisation. He is currently a member of the UK Dept Health Advisory Committee on Carcinogenicity, the Grant Review Panel for the MRC Integrated Toxicology Training Programme, the Strategic Governing Group on Translational Safety for the European Union’s Innovative Medicines Initiative, Chair of the British Pharmaceutical Industry Association Committee on Experimental Safety and Vice President of the British Toxicology Society.
